Acumulado Julio - Diciembre 2021 (87 - 88) 87
ISSN 1317-987X
 
Buscar




Artículos
 



Cardiología
Efecto de dos inhibidores de la fosfodiesterasa 5, sildenafil y vardenafil sobre la arteria pulmonar principal de la rata sometida a condiciones de hipoxia

Referencias bibliográficas

  1. Carvajal , J; Germain, A; Huidobro-Toro, J and keiner, C. Molecular mechanism of cGMP- mediatedsmoothmusclerelaxation. J. Cell. Physiol. 184: 409-420. 2000
  2. Priest R, Hucks D, and Ward JPT. Potentiation of cyclic AMP-mediated vasorelaxation by phenylephrine in pulmonary arteries of the rat. Br J Pharmacol 127: 291-299, 1997.
  3. Ghofrani, B. Tsai, H. Wang, Mark W. Turrentine, Y. Mahomed, John W. Brown, y col, Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies. Ann ThoracSurg. 78:360-368. 2004
  4. Pauvert O, Marthan R, and Savineau JP. NO-induced modulation of calcium-oscillations in pulmonary vascular smooth muscle. Cell Calcium 27: 329-338, 2000
  5. Polson J and Strada S.Cyclic nucleotide phosphodiesterases and vascular smooth muscle.Annu Rev PharmacolToxicol 36: 403-427, 1996
  6. Pauvert O, Savail D, Rousseau E, Lugnier C, Marthan R, and Savineau J. Characterization of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 63: 1763-1772, 2002
  7. Rabe K, Tenor H, Dent G, Schudt C, Nakashima M, and Magnussen H. 1dentification of PDE isoenzymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol Lung Cell MolPhysiol 266: L536-L543, 1994
  8. Marthan R, Castaing Y, Manier G, and Guenard H. Gas exchange alterations in patients with chronic obstructive lung disease. Chest 87: 470-475, 1985.
  9. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia.Respir Care 45: 39-51, 2000
  10. Dawson CA. Role of pulmonary vasomotion in physiology of the lung. Physiol Rev 64: 544-616, 1984.
  11. Hanson K, Burns F, Rybalkin S, Miller J, Beavo J, and Clarke W. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 158: 279-288, 1998.
  12. Stoclet J, Keravis T, Komas N, and Lugnier C. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. ExpOpin 1nvest Drugs 4: 1081-100, 1995
  13. Michelakis E, Tymchak W, Noga M, Webster L, Wu XC, y col, Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108: 2066-2069, 2003.
  14. Murray F, MacLean M, and Pyne N. 1ncreased expression on the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137: 1187-1194, 2002.
  15. Hanson K, Ziegler J, Rybalkin S, Miller J, Abman S, and Clarke W. Chronic pulmonary hypertension increases fetal lung cGMPphosphodiesterase activity. Am J Physiol Lung Cell MolPhysiol 275: L931-L941, 1998.
  16. Chinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, y col, Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29: 1000-1005, 2001
  17. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation 105: 2398-2403, 2002.
  18. Sebkhi A, Strange J, Phillips S, Wharton J, and Wilkins M. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107: 3230-3235, 2003.
  19. Wilkins, M; Wharton, J; Grimminger, F. and Ghofrani, H. Phospodiesterase inhibitors for the treatment of pulmonary hypertension. Eur. Respire J. 32: 198-209. 2008
  20. Lalande S, Snyder E, Olson T, Hulsebus M, Orban M, Somers V, Johnson B and Frantz R.The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise.Eur J Appl Physiol. 106(4):509-515. 2009
  21. Khalil 2010. Regulation of Vascular Smooth Muscle Function. Raouf A. Khalil 2010 by Morgan & Claypool Life Sciences. Colloquium Series on Integrated Systems Physiology. [En línea] http://www.fishpond.com.au/Books/Regulation­of­ Vascular­Smooth­Muscle­Function­Colloquium­Series­on­Integrated­Systems­Physiology­Raouf­Khalil­D­Neil­Granger­Series­edited­by/9781615041800 [Consulta: 30 de Agosto de 2013]
  22. Furchgott , R and Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.Nature 288, 373-376. 1980
  23. Ghofrani, H; Voswinckel, R; Reichenberger, F; Olschewski, H; Haredza, P y col. Differences in hemodynamic and oxygenation response to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J. Am. Coll Cardiol. 2004. 44(7): 1488-1496
  24. Resta, T; Kanagy, N. and Walker, B. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am. J. Physiol. 280: L88-L97, 2001
  25. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH and Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152.
  26. Cleber E. Teixeira, Fernanda B. M. Priviero, and R. Clinton Webb.Differential Effects of the Phosphodiesterase Type 5 1nhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta.JPET 316:654-661, 2006
  27. Teixeira, C. Priviero, F. and R. Webb, C. Differential Effects of the Phosphodiesterase Type 5 1nhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta.JPET 316:654-661, 2006
  28. Pauvert O, Bonnet S, Rousseau E, Marthan R, and Savineau J. Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol 287: L577-L583. 2004
  29. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry 1, and Oka M. Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol. 287: L665-L672. 2004
  30. Zhao, N. A. Mason, ; N. W. Morrell; B. Kojonazarov, A. Sadykov, A. Maripov, y col, Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 24;104(4):424-8. 2001
  31. Mochida H, 1noue H, Takagi M, Noto T, Yano K, and Kikkawa K . Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. Eur J Pharmacol 440: 45-52. 2002
  32. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation 105: 2398-2403, 2002.
  33. Andersen C, Mulvany M, and Simonsen U. Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. Eur J Pharmacol 510: 87-96. 2005
  34. Pauvert O, Bonnet S, Rousseau E, Marthan R, and Savineau J. Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol 287: L577-L583. 2004
  35. Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, and Savineau JP. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br J Pharmacol 139: 513-522, 2003
  36. Murray F, MacLean MR, and Pyne NJ. 1ncreased expression on the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137: 1187-1194.
  37. Ghofrani H, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F.Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.Lancet. 2002;360(9337):895-900
  38. Michelakis E, Tymchak W, Noga M, Webster L, Wu XC, y col, Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108: 2066-2069, 2003.
  39. Savineau JP, Gonzalez de la Fuente P, and Marthan R. Effect of vascular smooth muscle relaxants on the protein kinase C-mediated contraction in the rat pulmonary artery. Eur J Pharmacol 249: 191-198, 1993.
  40. Kirsch, M., Kemp-Harper, B., Weissmann, N., Grimminger, F., Schmidt, H. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. The FASEB Journal. 2008;22:30-40
  41. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia.Respir Care 45: 39-51, 2000
  42. Ghofrani, H; Voswinckel, R; Reichenberger, F; Olschewski, H; Haredza, P y col. Differences in hemodynamic and oxygenation response to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J. Am. Coll Cardiol. 2004. 44(7): 1488-1496
  43. Risau W. Mechanisms of angiogenesis. Nature. 1997;386: 671– 674.
  44. Makoto, S., Sata, M., Toshihiro, M., Toshiaki, N, , Yasunobu, H. and Ryozo, N. A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G–Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway. Arterioscler Thromb Vasc Biol 2010, 30:1315-1324.
  45. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16: 4604–4613
  46. Schlossmann, J. and Schinner, E. cGMP becomes a drug target. Naunyn-Schmiedeberg's Arch Pharmacol. 385: 243–252. 2012
  47. Cohen AH, Hanson K, Morris K, et al. Inhibition of cyclic 3’-5’-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996;97:172–9.
  48. Tsai, B; Mark W; Turrentine, M, Sheridan y col. ,Differential Effects of Phosphodiesterase-5 Inhibitors on Hypoxic Pulmonary Vasoconstriction and Pulmonary Artery Cytokine Expression. Ann Thorac Surg 2006;81:272– 8
  49. Golombek, S; Sola, A; Lemus, L. y col. Recomendaciones del VI Consenso Clínico de SIBEN para la Hipertensión Pulmonar Persistente del Recién Nacido. NeoReviews. 2017; 18: e327-3440

Efecto de dos inhibidores de la fosfodiesterasa 5, sildenafil y vardenafil sobre la arteria pulmonar principal de la rata sometida a condiciones de hipoxia
Introducción
Materiales y métodos
Resultados
Discusión
Referencias bibliográficas

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.





Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit